ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC30568-5mg |
|
847991-34-8 |
MARK Substrate
|
0 | C60H108N18O21 | |
GC30568-1mg |
|
847991-34-8 |
MARK Substrate
|
0 | C60H108N18O21 | |
GC30567-1g |
|
88122-99-0 |
Ethylhexyl triazone (Octyl triazone)
|
0 | C48H66N6O6 | |
GC30567-500mg |
|
88122-99-0 |
Ethylhexyl triazone (Octyl triazone)
|
0 | C48H66N6O6 | |
GC30567-100mg |
|
88122-99-0 |
Ethylhexyl triazone (Octyl triazone)
|
0 | C48H66N6O6 | |
GC30567-10mM(1mLinDMSO) |
|
88122-99-0 |
Ethylhexyl triazone (Octyl triazone)
|
0 | C48H66N6O6 | |
GC30566-1mg |
|
151606-29-0 |
Zinquin
|
0 | C19H18N2O5S | |
GC30565-100mg |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30565-50mg |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30565-10mg |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30565-5mg |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30565-1mg |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30565-10mM(1mLinDMSO) |
|
1612191-86-2 |
BAR502
|
0 | C25H44O3 | |
GC30564-100mg |
|
673-22-3 |
2-Hydroxy-4-methoxybenzaldehyde
|
0 | C8H8O3 | |
GC30563-5mg |
|
1394157-34-6 |
Sofosbuvir impurity N
|
0 | C20H25FN3O9P | |
GC30563-1mg |
|
1394157-34-6 |
Sofosbuvir impurity N
|
0 | C20H25FN3O9P | |
GC30563-10mM(1mLinDMSO) |
|
1394157-34-6 |
Sofosbuvir impurity N
|
0 | C20H25FN3O9P | |
GC30562-100mg |
|
880155-70-4 |
CNT2 inhibitor-1
|
0 | C23H24N6O4 | |
GC30562-50mg |
|
880155-70-4 |
CNT2 inhibitor-1
|
0 | C23H24N6O4 | |
GC30562-25mg |
|
880155-70-4 |
CNT2 inhibitor-1
|
0 | C23H24N6O4 | |